Everything drug pricing and policy, every day
And a critical 2026 trend -- dropping list prices on blockbuster drugs -- has begun with a 40%+ cut to Imbruvica’s price
And the results of the “Nobody Knows” Prediction Contest
Plus, a rosy AARP survey suggests that Medicare “negotiations” will lower out-of-pocket costs. The truth is likely to be more complicated.
And introducing the first annual ‘Nobody Knows’ Prediction Contest
And Pfizer’s take on the pharm-to-table opportunity in obesity: ‘Multiples of what we were expecting’
And Pfizer offers few new details on how the MFN deal will impact the company’s bottom line next year
My research with Tufts CEVR on drug-price announcements, published today in AJMC, assessed 150 meds over three years
And a Tufts CEVR analysis suggests that cost-effectiveness is not playing a meaningful role in government price-setting efforts
And an evolving list of all of the pricing and policy fun to be had between now and Christmas
